According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) has demonstrated similar clinical outcomes and significant patient benefits when compared to traditional intensity modulated radiation therapy (IMRT) as part of chemoradiation treatment for patients with oropharyngeal (head and neck) cancer.
[block_2]
The groundbreaking results were unveiled today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Dr. Steven Frank, professor of Radiation Oncology and executive director of the Particle Therapy Institute at MD Anderson.
Stay connected to UKNIP via Google News
ENJOYED THIS STORY? Choose UKNIP as a 'Preferred Source' on Google News for quick access to the news you value.
